Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Short-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Less: Average payables payment period

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


An examination of short-term operating activity ratios reveals fluctuating performance over the observed period. Inventory turnover generally decreased from March 2022 through December 2023, before exhibiting a substantial increase in the latter half of 2024 and continuing into the first half of 2025. Accounts payable turnover demonstrated a similar pattern of decline followed by improvement, though less pronounced than that of inventory turnover. Working capital turnover displayed significant volatility throughout the period, with notable spikes in certain quarters. The average inventory processing period lengthened from March 2022 to December 2024, then contracted sharply in 2025. Conversely, the average payables payment period generally increased through December 2024, before decreasing in the first half of 2025.

Inventory Turnover
Inventory turnover exhibited a consistent decline from 4.55 in March 2022 to 3.70 in March 2024. However, a marked increase occurred in December 2024, reaching 5.46, and remained elevated through June 2025 at 5.18. This suggests a potential improvement in inventory management efficiency in late 2024 and early 2025, possibly due to increased sales or more effective inventory control measures.
Payables Turnover
Payables turnover followed a broadly similar trend to inventory turnover, decreasing from 3.25 in March 2022 to 3.12 in March 2024. An upward trend was then observed, peaking at 3.90 in December 2025. This indicates a fluctuating ability to efficiently manage and pay off supplier obligations, with a recent improvement in the rate at which payables are settled.
Working Capital Turnover
Working capital turnover demonstrated the most significant fluctuations. A high of 8.30 was recorded in December 2022, followed by a low of 4.60 in September 2023. A substantial increase to 15.56 occurred in March 2024, before decreasing to 7.83 in December 2024. The ratio then showed some recovery, reaching 8.09 in June 2025. This volatility suggests inconsistent efficiency in utilizing working capital to generate sales.
Average Inventory Processing Period
The average inventory processing period lengthened from 80 days in March 2022 to 99 days in March 2024, indicating that inventory was taking longer to convert into sales. However, a significant decrease was observed in December 2024, falling to 67 days, and remained relatively stable through June 2025 at 70 days. This suggests a recent improvement in the speed of inventory turnover.
Average Payables Payment Period
The average payables payment period generally increased from 112 days in March 2022 to 120 days in June 2024, suggesting a lengthening of the time taken to settle obligations to suppliers. A decrease was then observed, falling to 94 days in December 2025, indicating a faster rate of payment. The peak of 140 days in June 2025 warrants further investigation.

Overall, the observed trends suggest a period of operational challenges followed by potential improvements in inventory and payables management in late 2024 and early 2025. The volatility in working capital turnover warrants further scrutiny to understand the underlying drivers and potential risks.


Turnover Ratios


Average No. Days


Inventory Turnover

Bristol-Myers Squibb Co., inventory turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Inventory turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ4 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ2 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ1 2025) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


Inventory turnover exhibited fluctuating behavior over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a relatively stable turnover, followed by a period of decline, and then a subsequent increase towards the end of the analyzed timeframe.

Initial Stability and Subsequent Decline (Mar 31, 2022 – Dec 31, 2022)
From March 31, 2022, through December 31, 2022, the inventory turnover ratio remained relatively consistent, ranging between 4.33 and 4.77. This suggests a stable rate at which inventory was being sold and replenished during this period. However, a gradual downward trend became apparent, culminating in a ratio of 4.02 by the end of 2022.
Continued Decline and Low Point (Mar 31, 2023 – Dec 31, 2023)
The downward trend continued into the first three quarters of 2023, reaching a low of 3.70 in March 2023. The ratio remained below 4.0 for the remainder of 2023, indicating a slower rate of inventory conversion. This period may reflect factors such as increased inventory levels, decreased sales, or a combination of both.
Significant Increase and Stabilization (Mar 31, 2024 – Dec 31, 2025)
A substantial increase in inventory turnover was observed beginning in December 2024, with a ratio of 5.46. This increase continued into 2025, with ratios fluctuating between 5.18 and 5.31. The final reported value, 5.18 as of December 31, 2025, suggests a significantly improved efficiency in inventory management compared to the period between March 2023 and September 2024. The increase could be attributed to successful inventory reduction strategies, increased demand for products, or a change in inventory valuation methods.
Cost of Products Sold and Inventory Relationship
The cost of products sold generally increased over the period, with a notable jump in December 2024. This increase in cost of goods sold appears to correlate with the subsequent increase in inventory turnover, suggesting that higher sales volumes contributed to the improved turnover ratio. Inventory levels also fluctuated, peaking at 3,332 in June 2024 before declining to 2,690 by December 2025, further supporting the observation of improved inventory management.

Overall, the inventory turnover ratio demonstrates a cyclical pattern, with a period of decline followed by a significant recovery. The recent increase in turnover suggests positive developments in inventory management and sales efficiency.


Payables Turnover

Bristol-Myers Squibb Co., payables turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets
Accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Payables turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ4 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ2 2025 + Cost of products sold, excludes amortization of acquired intangible assetsQ1 2025) ÷ Accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The payables turnover ratio for the analyzed period demonstrates fluctuations, generally remaining within a relatively narrow range with some notable deviations. An initial observation reveals a generally stable, albeit slightly declining, trend over the first three years, followed by more pronounced variability in the final year of the observation period.

Overall Trend
From March 2022 through December 2023, the payables turnover ratio exhibited a moderate degree of fluctuation, averaging approximately 3.33. The ratio began at 3.25, peaked at 3.82 in September 2022, and then settled back to around 3.30 before declining to 3.28 by the end of 2023. This suggests a consistent, but not dramatically changing, relationship between cost of products sold and accounts payable during this timeframe.
Recent Fluctuations
A more significant shift is observed from March 2024 onwards. The ratio decreased to 3.12 in March 2024, then 3.05 in June 2024, indicating a potential slowing in the rate at which the company pays its suppliers. A subsequent increase to 3.88 in December 2024 suggests a reversal of this trend, potentially due to seasonal factors or a deliberate change in payment strategy. However, this increase was not sustained, with the ratio falling to 2.61 in June 2025, the lowest value in the observed period. A partial recovery to 3.90 by December 2025 is noted, but the overall trend for the final year is characterized by increased volatility.
Relationship to Cost of Products Sold and Accounts Payable
The fluctuations in the payables turnover ratio appear to correlate with changes in both cost of products sold and accounts payable. The decrease in the ratio during the first half of 2024 coincided with increases in both of these values, while the sharp decline in June 2025 occurred alongside a substantial increase in accounts payable. The December 2025 increase in the ratio is associated with a significant increase in cost of products sold, while accounts payable decreased.

In conclusion, while the payables turnover ratio demonstrated relative stability for the majority of the analyzed period, the final year exhibited increased variability. Further investigation may be warranted to understand the drivers behind these recent fluctuations and their potential impact on the company’s financial position and operational efficiency.


Working Capital Turnover

Bristol-Myers Squibb Co., working capital turnover calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Net product sales
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Working capital turnover = (Net product salesQ4 2025 + Net product salesQ3 2025 + Net product salesQ2 2025 + Net product salesQ1 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The working capital turnover ratio exhibits considerable fluctuation over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicate a decline from 6.24 to 4.92 in the first half of 2022, followed by a moderate increase to 5.75 by September 30, 2022, and a substantial rise to 8.30 by the end of that year. This pattern suggests potential seasonal influences or shifts in operational efficiency during 2022.

2023 Overview
The ratio began 2023 at 5.55, remaining relatively stable at 5.53 for the subsequent quarter. A significant surge to 10.47 was then observed in the third quarter of 2023, before declining sharply to 4.60 in the final quarter. This volatility suggests considerable changes in the relationship between working capital and net product sales throughout the year.

The first half of 2024 demonstrates a strong upward trend, with the ratio increasing from 15.56 in March to 12.50 in June. This is followed by a decrease to 8.49 and 7.79 in the subsequent quarters. The ratio then stabilizes somewhat, fluctuating between 6.87 and 8.09 through the first three quarters of 2025, before ending the period at 7.83.

Long-Term Trends
Over the entire period, the working capital turnover ratio does not demonstrate a clear, consistent trend. While there are periods of increase and decrease, the ratio generally oscillates within a range of approximately 4.60 to 15.56. The highest values are concentrated in the first half of 2024, while the lowest values are observed in the first half of 2022 and the final quarter of 2023.
Recent Performance
The most recent quarters (September 30, 2025, and December 31, 2025) show a ratio around 6.20 and 7.83 respectively. This suggests a potential stabilization, although further observation is needed to confirm this trend. The fluctuations throughout the period indicate that the company’s efficiency in utilizing its working capital to generate sales is subject to change.

The observed variations warrant further investigation into the underlying drivers of these changes, including potential shifts in inventory management, accounts receivable collection periods, and accounts payable payment terms. A deeper analysis of these factors could provide valuable insights into the company’s operational performance and financial health.


Average Inventory Processing Period

Bristol-Myers Squibb Co., average inventory processing period calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average inventory processing period exhibited a fluctuating pattern over the observed timeframe. Initially, the period demonstrated a slight decrease, followed by a period of increase, and then a significant reduction before stabilizing.

Initial Trend (Mar 31, 2022 – Dec 31, 2022)
From March 31, 2022, to December 31, 2022, the average inventory processing period generally decreased, moving from 80 days to 76 days, with a slight increase to 84 days in the final quarter. This suggests an initial improvement in inventory management efficiency, potentially due to faster sales or more effective supply chain practices, followed by a minor reversal.
Increasing Period (Mar 31, 2023 – Dec 31, 2023)
The period then increased consistently from 93 days in March 2023 to 99 days in March 2024, peaking at 102 days in June 2024, and remaining at 98 days by December 2024. This indicates a lengthening of the time required to process inventory, potentially due to slower sales, increased inventory levels, or disruptions in the supply chain.
Significant Reduction and Stabilization (Mar 31, 2025 – Dec 31, 2025)
A substantial decrease in the average inventory processing period occurred between March 2025 and December 2025, falling from 69 days to 70 days. This sharp decline suggests a significant improvement in inventory turnover and processing efficiency. The period remained relatively stable at 70 days through the end of the observed period.
Correlation with Inventory Turnover
The observed trends in the average inventory processing period correlate inversely with the inventory turnover ratio. As inventory turnover decreased from 4.55 to a low of 3.57, the processing period increased. Conversely, the increase in inventory turnover from 3.57 to 5.18 coincided with a decrease in the processing period. This relationship confirms the expected inverse correlation between these two metrics.

Overall, the company experienced a dynamic period regarding inventory management. The initial efficiency gains were followed by a period of slower processing, ultimately culminating in a substantial improvement and stabilization towards the end of the analyzed timeframe.


Average Payables Payment Period

Bristol-Myers Squibb Co., average payables payment period calculation (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q4 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The average payables payment period exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. An initial decreasing trend was followed by periods of increase and relative stability, culminating in a final period of decline.

Overall Trend
From March 31, 2022 (112 days) to September 30, 2022 (96 days), a general decrease in the average payables payment period was observed. This suggests the company was, on average, settling its obligations to suppliers more quickly during this timeframe. Following this, the period increased to 109 days by December 31, 2022, before fluctuating between 97 and 120 days through the first three quarters of 2023. The period then decreased to 94 days by December 31, 2025.
Peak and Trough Values
The longest average payables payment period occurred on March 31, 2025, at 140 days. This represents a significant deviation from the period’s typical range. The shortest period was observed on September 30, 2022, at 96 days.
Recent Performance (2024-2025)
The period increased from 117 days on March 31, 2024, to 120 days on June 30, 2024, before decreasing to 94 days by December 31, 2025. The substantial increase to 140 days in June 2025 is notable and warrants further investigation. The subsequent decrease to 94 days by the end of the year suggests a potential correction or temporary factor influencing payment practices.
Relationship to Payables Turnover
The average payables payment period demonstrates an inverse relationship with the payables turnover ratio, as expected. When payables turnover increased, the average payment period tended to decrease, and vice versa. For example, the increase in payables turnover from 3.43 to 3.88 between September 30, 2024, and December 31, 2024, coincided with a decrease in the average payment period from 106 to 94 days.